When superficial spreading melanoma reaches stage IV, the cancer has spread beyond its original location to distant parts of the body. Understanding how doctors diagnose this advanced stage and the tests used to monitor the disease can help patients navigate their treatment journey with greater confidence.

Introduction: Who Should Undergo Diagnostics

People who notice unusual changes in their skin should seek medical attention promptly. If you observe a new mole appearing on your skin, or if an existing mole starts to change in size, shape, or color, these are important warning signs that deserve evaluation by a healthcare professional. The earlier melanoma is detected, the better the chances of successful treatment, as melanomas caught in the earliest stages have very high cure rates.^[1]

Certain individuals should be particularly vigilant about seeking diagnostic evaluation. If you have fair skin that burns easily, a history of blistering sunburns, or multiple unusual-looking moles, you belong to a higher-risk group. People with a strong family history of melanoma, especially when two or more close family members have been affected, should also be more attentive to skin changes. Additionally, if you have more than five atypical moles (moles that look unusual or funny compared to normal moles), you should consider regular skin examinations.^[2]

The location of suspicious spots matters too. In men, melanoma commonly develops on the trunk, which includes the chest, back, and upper body, or on the head and neck. In women, melanoma most frequently appears on the legs. However, melanoma can develop anywhere on the body, including areas that receive little sun exposure.^[2]

You should contact a doctor if you notice any spot on your skin that displays certain characteristics. These warning signs are remembered through the ABCDE rule: Asymmetry (one half doesn’t match the other), Border irregularity (edges are not smooth), Color variation (multiple colors or uneven shades), Diameter greater than 6 millimeters (about the size of a pencil eraser), and Evolving (the spot is changing in size, shape, or color). Not all melanomas follow this pattern, so any persistent sores that won’t heal, unusual bumps, or changes in existing moles warrant medical evaluation.^[5]

Classic Diagnostic Methods for Identifying Melanoma

The diagnostic process for melanoma begins with a thorough examination of your skin. A healthcare professional, typically a dermatologist who specializes in skin conditions, will carefully inspect the suspicious area and may also check other parts of your body for additional concerning spots. During this physical examination, the doctor looks for signs that match the characteristics of melanoma, paying attention to the appearance, borders, colors, and any changes in skin lesions.^[1]

Biopsy: The Definitive Diagnostic Test

When a suspicious skin lesion is identified, a biopsy must be performed to confirm whether melanoma is present. During a biopsy, the doctor removes a sample of tissue from the suspicious area so it can be examined under a microscope in a laboratory. This is the only way to definitively determine if cancer cells are present. The tissue sample is sent to a specialist doctor called a pathologist, who studies the cells to identify whether they are cancerous and, if so, what type of cancer it is.^[1]

There are several types of biopsies that may be used. An excisional biopsy is the preferred method for suspected melanoma. This procedure uses a scalpel to remove the entire suspicious growth along with a small amount of surrounding healthy skin. Stitches are typically needed to close the wound after this type of biopsy. Another approach is the punch biopsy, where a round-tipped cutting tool is pressed into the skin to remove deeper layers of tissue. The size of the sample determines whether stitches will be necessary afterward.^[16]

The biopsy serves multiple purposes beyond simply confirming the presence of melanoma. When examined under a microscope, the pathologist can determine important characteristics of the cancer, including how thick it is. The thickness of the melanoma, measured from the top layer of skin down to the deepest point where cancer cells are found, is one of the most important factors in determining the stage and likely course of the disease. The pathologist will also check whether the top layer of the melanoma appears broken or damaged, a condition called ulceration, which provides additional information about the cancer’s behavior.^[1]

Staging Tests After Diagnosis

Once melanoma is confirmed through biopsy, additional tests and scans are usually performed to determine whether the cancer has spread beyond the original site. This process, called staging, helps doctors understand how advanced the cancer is and plan appropriate treatment. For stage 4 melanoma specifically, the cancer has already spread to distant parts of the body, far from where it originally developed.^[1]

Blood tests are one component of the diagnostic workup. These tests can provide information about your overall health and how well your organs are functioning. For example, blood tests may check your blood count and evaluate liver function, which can be affected if melanoma has spread to the liver. While blood tests don’t directly diagnose melanoma, they help doctors understand how the disease may be affecting your body.^[8]

Imaging scans play a crucial role in identifying where melanoma has spread. Several types of imaging studies may be used. Ultrasound uses sound waves to create pictures of the inside of the body and can help examine soft tissues and lymph nodes. Computed tomography (CT) scans use specialized X-ray equipment to create detailed cross-sectional images of the body, helping to detect cancer in organs like the lungs, liver, or other internal structures. Magnetic resonance imaging (MRI) uses powerful magnets and radio waves to generate detailed images of soft tissues, and is particularly useful for examining the brain and spinal cord to check for cancer spread.^[1]

In stage 4 melanoma, the cancer has traveled beyond nearby lymph nodes to more distant areas. The most common sites where melanoma spreads include the lungs, liver, bones, brain, and gastrointestinal tract. It can also spread to distant points on the skin or to soft tissue, which includes muscles, nerves, fat, and blood vessels. Sometimes the cancer spreads to more than one area simultaneously. These distant locations where cancer has traveled are called secondary cancers or metastases.^[1]

TNM Staging System

Doctors use a detailed classification system called the TNM staging system to describe melanoma precisely. TNM stands for Tumor, Node, and Metastasis. The “T” describes characteristics of the original tumor, including its size and thickness. The “N” indicates whether cancer cells have spread to lymph nodes and how many nodes are affected. The “M” tells whether the cancer has spread to distant parts of the body. In stage 4 melanoma, the TNM classification is written as “Any T, Any N, M1,” meaning the original tumor can be any size, any number of lymph nodes may be involved, and distant metastasis is present.^[1]

Diagnostics for Clinical Trial Qualification

When patients with stage 4 melanoma are being considered for participation in clinical trials (research studies testing new treatments), specific diagnostic tests are required to determine eligibility. Clinical trials have strict criteria about which patients can participate, and comprehensive testing helps ensure that patients are suitable candidates for the experimental treatments being studied.^[1]

The baseline diagnostic evaluation for clinical trial enrollment typically mirrors the standard diagnostic workup but may be more extensive. Patients will need recent imaging scans to document exactly where the cancer has spread and how large the tumors are. These baseline images are essential because doctors will compare them to later scans to determine whether the treatment being tested is working. The specific imaging studies required depend on the trial protocol, but commonly include CT scans of the chest, abdomen, and pelvis, as well as MRI scans of the brain.^[4]

Blood tests are another standard component of clinical trial screening. These tests assess overall health and organ function to ensure patients can safely tolerate the experimental treatment. Liver function tests, kidney function tests, and complete blood counts are typically required. Some trials may also test for specific biomarkers, which are measurable substances in the blood or tumor tissue that provide information about the cancer’s characteristics or likely response to treatment.^[8]

For certain clinical trials, especially those testing targeted therapies, tumor tissue from the biopsy may need to undergo additional molecular testing. Some melanomas have specific genetic changes, such as mutations in a gene called BRAF, which occurs in many superficial spreading melanomas. Knowing whether these mutations are present helps match patients to clinical trials testing drugs designed to target those specific genetic changes. This molecular profiling requires examination of tumor tissue in specialized laboratories.^[2]

The clinical trial screening process also includes a thorough review of medical history and current health status. Doctors conducting the trial need to know about other medical conditions, medications being taken, and any previous cancer treatments. This comprehensive evaluation ensures that patients enrolled in the trial are appropriate candidates who can be safely monitored throughout the study period.^[4]

Throughout participation in a clinical trial, patients undergo regular monitoring with repeated diagnostic tests. These follow-up evaluations track how the cancer responds to treatment and watch for any side effects. The frequency and types of tests depend on the specific trial protocol, but typically include periodic imaging scans and blood tests at scheduled intervals. This ongoing monitoring provides valuable data about the treatment’s effectiveness and safety, benefiting both the individual participant and the broader scientific community working to improve melanoma care.^[4]